Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib.
10.3779/j.issn.1009-3419.2021.102.25
- Author:
Liling HUANG
1
;
Yan QIN
1
;
Fengyi ZHAO
1
;
Shengyu ZHOU
1
;
Yuankai SHI
1
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study
on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Anlotinib;
Anti-angiogenesis;
Immunotherapy;
Lung neoplasms;
Pembrolizumab
- MeSH:
Adenocarcinoma of Lung/genetics*;
Aged, 80 and over;
Antibodies, Monoclonal, Humanized;
Antineoplastic Combined Chemotherapy Protocols;
Carcinoma, Non-Small-Cell Lung/genetics*;
ErbB Receptors/genetics*;
Female;
Humans;
Indoles;
Lung Neoplasms/genetics*;
Mutation;
Quinolines
- From:
Chinese Journal of Lung Cancer
2021;24(10):739-742
- CountryChina
- Language:Chinese
-
Abstract:
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
.
